{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:48:04Z","timestamp":1777186084706,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,25]]},"DOI":"10.7759\/cureus.107718","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:23:12Z","timestamp":1777184592000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of High-Dose Rifampicin in the Management of Tuberculosis Meningitis: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Syed Saad","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wifag Medani","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandhya","family":"Narahari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani Badal","family":"Hayder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naheemat Mofolasayo","family":"Salimon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warda Batool","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Reji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roa","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipak","family":"Chaulagain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aashan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulqadir  J","family":"Nashwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. tuberculosis. (2025). Accessed: April 3, 2026: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa257","article-title":"Treatment outcomes in adult tuberculous meningitis: a systematic review and meta-analysis","volume":"7","author":"Stadelman AM","year":"2020","unstructured":"Stadelman AM, Ellis J, Samuels TH, et al.. Treatment outcomes in adult tuberculous meningitis: a systematic review and meta-analysis. Open Forum Infect Dis. 2020, 7:ofaa257. 10.1093\/ofid\/ofaa257","journal-title":"Open Forum Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-019-0966-8","article-title":"Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis","volume":"19","author":"Wang MG","year":"2019","unstructured":"Wang MG, Luo L, Zhang Y, Liu X, Liu L, He JQ. Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis. BMC Pulm Med. 2019, 19:200. 10.1186\/s12890-019-0966-8","journal-title":"BMC Pulm Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/798764","article-title":"Tuberculous meningitis: diagnosis and treatment overview","volume":"2011","author":"Marx GE","year":"2011","unstructured":"Marx GE, Chan ED. Tuberculous meningitis: diagnosis and treatment overview. Tuberc Res Treat. 2011, 2011:798764. 10.1155\/2011\/798764","journal-title":"Tuberc Res Treat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2023.07.003","article-title":"Rifampicin drug resistance and host immunity in tuberculosis: more than meets the eye","volume":"44","author":"Bobba S","year":"2023","unstructured":"Bobba S, Khader SA. Rifampicin drug resistance and host immunity in tuberculosis: more than meets the eye. Trends Immunol. 2023, 44:712-23. 10.1016\/j.it.2023.07.003","journal-title":"Trends Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf178","article-title":"Population pharmacokinetics of rifampicin in plasma and cerebrospinal fluid in adults with tuberculosis meningitis","volume":"232","author":"Abdelgawad N","year":"2025","unstructured":"Abdelgawad N, Wasserman S, Gausi K, et al.. Population pharmacokinetics of rifampicin in plasma and cerebrospinal fluid in adults with tuberculosis meningitis. J Infect Dis. 2025, 232:e234-41. 10.1093\/infdis\/jiaf178","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab162","article-title":"High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly human immunodeficiency virus (HIV)-positive Ugandan adults: a Phase II open-label randomized controlled trial","volume":"73","author":"Cresswell FV","year":"2021","unstructured":"Cresswell FV, Meya DB, Kagimu E, et al.. High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly human immunodeficiency virus (HIV)-positive Ugandan adults: a Phase II open-label randomized controlled trial. Clin Infect Dis. 2021, 73:876-84. 10.1093\/cid\/ciab162","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.822201","article-title":"Intensified antituberculosis therapy regimen containing higher dose rifampin for tuberculous meningitis: a systematic review and meta-analysis","volume":"9","author":"Zhang M","year":"2022","unstructured":"Zhang M, Wang M, He JQ. Intensified antituberculosis therapy regimen containing higher dose rifampin for tuberculous meningitis: a systematic review and meta-analysis. Front Med (Lausanne). 2022, 9:822201. 10.3389\/fmed.2022.822201","journal-title":"Front Med (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502866","article-title":"Trial of high-dose oral rifampin in adults with tuberculous meningitis","volume":"393","author":"Meya DB","year":"2025","unstructured":"Meya DB, Cresswell FV, Dai B, et al.. Trial of high-dose oral rifampin in adults with tuberculous meningitis. N Engl J Med. 2025, 393:2434-46. 10.1056\/NEJMoa2502866","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102857","article-title":"Efficacy and safety of higher dose rifampicin in adults with presumed drug-susceptible tuberculosis: an updated systematic review and meta-analysis","volume":"77","author":"Haigh KA","year":"2024","unstructured":"Haigh KA, Twabi HH, Boloko L, Namale PE, Lutje V, Nevitt S, Davies G. Efficacy and safety of higher dose rifampicin in adults with presumed drug-susceptible tuberculosis: an updated systematic review and meta-analysis. EClinicalMedicine. 2024, 77:102857. 10.1016\/j.eclinm.2024.102857","journal-title":"EClinicalMedicine"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.25259\/IJMR_1673_2024","article-title":"Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: a systematic review & meta-analysis","volume":"161","author":"Kannabiran BP","year":"2025","unstructured":"Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MK, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: a systematic review & meta-analysis. Indian J Med Res. 2025, 161:449-60. 10.25259\/IJMR_1673_2024","journal-title":"Indian J Med Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"Br Med J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br Med J. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"Br Med J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.06.016","article-title":"Pharmacokinetics and safety\/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients","volume":"48","author":"Yunivita V","year":"2016","unstructured":"Yunivita V, Dian S, Ganiem AR, et al.. Pharmacokinetics and safety\/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. Int J Antimicrob Agents. 2016, 48:415-21. 10.1016\/j.ijantimicag.2016.06.016","journal-title":"Int J Antimicrob Agents"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01014-18","article-title":"Double-blind, randomized, placebo-controlled phase II dose-finding study to evaluate high-dose rifampin for tuberculous meningitis","volume":"62","author":"Dian S","year":"2018","unstructured":"Dian S, Yunivita V, Ganiem AR, et al.. Double-blind, randomized, placebo-controlled phase II dose-finding study to evaluate high-dose rifampin for tuberculous meningitis. Antimicrob Agents Chemother. 2018, 62:01014-18. 10.1128\/AAC.01014-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac932","article-title":"A Phase 2a trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus-associated tuberculous meningitis: the LASER-TBM trial","volume":"76","author":"Davis AG","year":"2023","unstructured":"Davis AG, Wasserman S, Stek C, et al.. A Phase 2a trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus-associated tuberculous meningitis: the LASER-TBM trial. Clin Infect Dis. 2023, 76:1412-22. 10.1093\/cid\/ciac932","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami R","year":"2013","unstructured":"Ruslami R, Ganiem AR, Dian S, et al.. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013, 13:27-35. 10.1016\/S1473-3099(12)70264-5","journal-title":"Lancet Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified antituberculosis therapy in adults with tuberculous meningitis","volume":"374","author":"Heemskerk AD","year":"2016","unstructured":"Heemskerk AD, Bang ND, Mai NT, et al.. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med. 2016, 374:124-34. 10.1056\/NEJMoa1507062","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00140-21\u00a0","article-title":"Plasma pharmacokinetics of high-dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial","volume":"65","author":"Wasserman S","year":"2021","unstructured":"Wasserman S, Davis A, Stek C, et al.. Plasma pharmacokinetics of high-dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial. Antimicrob Agents Chemother. 2021, 65:00140-21. 10.1128\/AAC.00140-21\u00a0","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-025-05364-6","article-title":"High dose of rifampicin in the treatment of tuberculous meningitis: a systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Pu J","year":"2026","unstructured":"Pu J, Wu S, He JQ. High dose of rifampicin in the treatment of tuberculous meningitis: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Microbiol Infect Dis. 2026, 45:1105-13. 10.1007\/s10096-025-05364-6","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/ijmy.ijmy_135_21","article-title":"Safety and efficacy of high-dose rifampicin in the management of tuberculosis meningitis: systematic review and meta-analysis","volume":"10","author":"Charlie L","year":"2021","unstructured":"Charlie L, Abay SM, Tesfaye A, Mlera RN, Mwango S, Goretti M. Safety and efficacy of high-dose rifampicin in the management of tuberculosis meningitis: systematic review and meta-analysis. Int J Mycobacteriol. 2021, 10:312-9. 10.4103\/ijmy.ijmy_135_21","journal-title":"Int J Mycobacteriol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13555","article-title":"High-dose rifampicin for the treatment of tuberculous meningitis: a meta-analysis of randomized controlled trials","volume":"47","author":"Cao Y","year":"2022","unstructured":"Cao Y, Wang T, He K, Xue J, Wang X, Liang J. High-dose rifampicin for the treatment of tuberculous meningitis: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2022, 47:445-54. 10.1111\/jcpt.13555","journal-title":"J Clin Pharm Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/478293-efficacy-and-safety-of-high-dose-rifampicin-in-the-management-of-tuberculosis-meningitis-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:23:13Z","timestamp":1777184593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/478293-efficacy-and-safety-of-high-dose-rifampicin-in-the-management-of-tuberculosis-meningitis-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.107718","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,25]]}}}